Safety Study of AADvac1, a Tau Peptide-KLH-Conjugate Active Vaccine to Treat Alzheimer's Disease
Clinical trial NCT01850238 · COMPLETED
Trial details
- NCT number
- NCT01850238
- Sponsor
- Axon Neuroscience SE
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2013-05-01
- Primary completion
- 2015-03-01
- Enrollment
- 30
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.